Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo
The Journal of Infectious Diseases · 12.04.2024 · 229 (4) · 1068-1076
DOI: 10.1093/infdis/jiad350 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 24.08.2023. Verfasst von Ynke Larivière und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk. Hauptthemen laut MEDLINE: Ebola Vaccines, Ebolavirus, Hemorrhagic Fever, Ebola, Smallpox Vaccine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IMI2 Joint Undertaking, European Union's Horizon 2020, European Federation of Pharmaceutical Industries and Associations.
Abstract (Originalsprache)
Background
In response to recent Ebola epidemics, vaccine development against the Zaire ebolavirus (EBOV) has been fast-tracked in the past decade. Health care providers and frontliners working in Ebola-endemic areas are at high risk of contracting and spreading the virus.
Methods
This study assessed the safety and immunogenicity of the 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine regimen (administered at a 56-day interval) among 699 health care providers and frontliners taking part in a phase 2, monocentric, randomized vaccine trial in Boende, the Democratic Republic of Congo. The first participant was enrolled and vaccinated on 18 December 2019. Serious adverse events were collected up to 6 months after the last received dose. The EBOV glycoprotein FANG ELISA (Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay) was used to measure the immunoglobulin G–binding antibody response to the EBOV glycoprotein.
Results
The vaccine regimen was well tolerated with no vaccine-related serious adverse events reported. Twenty-one days after the second dose, an EBOV glycoprotein–specific binding antibody response was observed in 95.2% of participants.
Conclusions
The 2-dose vaccine regimen was well tolerated and led to a high antibody response among fully vaccinated health care providers and frontliners in Boende.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk.
- Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk.
- Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
- Janssen Vaccines & Prevention, Leiden, the Netherlands.
- Data Science Institute, Interuniversity Institute for Biostatistics and statistical Bioinformatics, UHasselt, Diepenbeek, Belgium.
ORCID-Profile: Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, Solange Milolo, Rachel Meta, Primo Kimbulu, Chelsea McLean, Niel Hens, Junior Matangila, Vivi Maketa, Patrick Mitashi, Hypolite Muhindo-Mavoko, Jean-Pierre Van Geertruyden, Pierre Van Damme
Förderung
- IMI2 Joint Undertaking
- European Union's Horizon 2020
- European Federation of Pharmaceutical Industries and Associations
- Coalition for Epidemic Preparedness Innovations
- Janssen Vaccines & Prevention
- BV
- European Union’s Horizon 2020
Zitieren
APA
Larivière, Y., Garcia-Fogeda, I., Zola Matuvanga, T., Isekah Osang'ir, B., Milolo, S., Meta, R., Kimbulu, P., Robinson, C., Katwere, M., McLean, C., Hens, N., Matangila, J., Maketa, V., Mitashi, P., Muhindo-Mavoko, H., Van Geertruyden, J. P., & Van Damme, P. (2024). Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of Infectious Diseases, 229(4), 1068-1076. https://doi.org/10.1093/infdis/jiad350
Vancouver
Larivière Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osang'ir B, Milolo S, Meta R, et al. Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of Infectious Diseases. 2024;229(4):1068-1076. doi:10.1093/infdis/jiad350
BibTeX
@article{Larivire2024,
author = {Larivière, Ynke and Garcia-Fogeda, Irene and Zola Matuvanga, Trésor and Isekah Osang'ir, Bernard and Milolo, Solange and Meta, Rachel and Kimbulu, Primo and Robinson, Cynthia and Katwere, Michael and McLean, Chelsea and Hens, Niel and Matangila, Junior and Maketa, Vivi and Mitashi, Patrick and Muhindo-Mavoko, Hypolite and Van Geertruyden, Jean-Pierre and Van Damme, Pierre},
title = {Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {229},
number = {4},
pages = {1068--1076},
doi = {10.1093/infdis/jiad350}
}
EUVIMED